Device Trial Radar · NCT03421561
ILLUMENATE Pivotal Post-Approval Study (PAS)
Last checked: Nov 19, 2026Latest source record: Feb 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Jun 18, 2013
Primary completion
Dec 8, 2017
Study completion Oct 6, 2020
Sponsor
- Lead sponsor
- Spectranetics CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 5, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ILLUMENATE Pivotal PAS is a continued follow-up study which will include 300 subjects from forty-three (43) sites across the United States and Austria previously enrolled in the ILLUMENATE Pivotal pre-market study to evaluate the Stellarex DCB compared to the PTA control device for the treatment of de-novo or post-PTA occluded/stenotic or reoccluded/restenotic (except for in-stent) SFA and/or popliteal arteries.
Conditions
- Peripheral Artery Disease
Interventions
Stellarex 0.035" OTW Drug-coated Angioplasty BalloonDevice
The Stellarex 0.035" OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.
EverCross™ 0.035 PTA Balloon CatheterDevice
The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Target Vessel Patency at 24 Months Post-procedureTime frame: 24 months post-procedure
- Number of Participants With Freedom From Device and Procedure Related Death Through 30 Days Post-procedure and Freedom From Target Limb Major Amputation and Clinically-driven Target Lesion Revascularization Through 24 Months Post-procedureTime frame: 24 months post-procedure
Locations
41 sites in 2 countries. Site status is shown where the registry gives one.
Yuma Regional Medical Center
Yuma, Arizona
Mission Cardiovascular Research Institute
Fremont, California
Good Samaritan Hospital - Los Angeles
Los Angeles, California
38 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.